SCHEMBL5653023

SCHEMBL5653023

CCN(CC)CCCNC(=O)c1ccc(-c2nc3cc4ccccc4cc3[nH]2)c(OC)c1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.50
WDR77 Q9BQA1 1/20 0.50
HTT P42858 1/20 0.47
HDAC6 Q9UBN7 2/20 0.46
TMEM97 Q5BJF2 2/20 0.46
SIGMAR1 Q99720 2/20 0.46
OPRM1 P35372 1/20 0.45
KMT2A Q03164 1/20 0.44
DRD2 P14416 2/20 0.44
DRD1 P21728 2/20 0.44
DRD4 P21917 2/20 0.44
DRD5 P21918 2/20 0.44
HTR2C P28335 2/20 0.44
DRD3 P35462 2/20 0.44
ROCK2 O75116 2/20 0.44
ROCK1 Q13464 2/20 0.44
GAA P10253 1/20 0.43
APP P05067 1/20 0.43
MCHR1 Q99705 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5653304 0.92 HDAC6 (0.47) PRMT5WDR77HTTHDAC6KMT2A
SCHEMBL5651251 0.90 PRMT5 (0.50) PRMT5WDR77HTTHDAC6TMEM97
SCHEMBL5651233 0.90 FLT3 (0.54) PRMT5WDR77HTTHDAC6TMEM97
SCHEMBL5650247 0.90 PRSS12 (0.50) PRMT5WDR77HTTHDAC6TMEM97
SCHEMBL5653615 0.88 HDAC6 (0.46) HTTHDAC6TMEM97SIGMAR1OPRM1
SCHEMBL5650314 0.88 HDAC6 (0.47) PRMT5WDR77HTTHDAC6TMEM97
SCHEMBL5652759 0.87 FLT3 (0.55) HDAC6ROCK2ROCK1
SCHEMBL5650220 0.87 PRMT5 (0.48) PRMT5WDR77HTTHDAC6TMEM97
SCHEMBL5650229 0.87 PRMT5 (0.48) PRMT5WDR77HTTHDAC6TMEM97
SCHEMBL5653858 0.86 PRMT5 (0.47) PRMT5WDR77HTTHDAC6TMEM97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 PRMT5 448/4885WDR77 1101/4885HTT 4354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.